Hepatocellular carcinoma is a leading cause of cancer-related death globally. The treatment of hepatocellular carcinoma is complex, with diverse therapeutic approaches and their combinations available ...

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...

A man living with advanced liver cancer has seen his tumour shrink by over half as “exciting” new clinical trials are ...

Waking up at 3am with discomfort from a pinched nerve in my shoulder, I reached for my phone in a panic. Within seconds, I ...

Opdivo plus Cometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.

Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with ...

A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the German Cancer Research Center (DKFZ), the Hector Institute für Translational ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the ...

However, the underlying mechanism regulating the function of liver T-ICs remains unclear. Methods Tissue microarrays containing 242 hepatocellular carcinoma (HCC) samples were used for prognostic ...